GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Corp (OTCPK:ALID) » Definitions » EV-to-EBITDA

Allied (Allied) EV-to-EBITDA : -3.10 (As of May. 21, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allied EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Allied's enterprise value is $24.77 Mil. Allied's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was $-7.99 Mil. Therefore, Allied's EV-to-EBITDA for today is -3.10.

The historical rank and industry rank for Allied's EV-to-EBITDA or its related term are showing as below:

ALID' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.21   Med: -3.65   Max: -1.03
Current: -3.1

During the past 6 years, the highest EV-to-EBITDA of Allied was -1.03. The lowest was -7.21. And the median was -3.65.

ALID's EV-to-EBITDA is ranked worse than
100% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.89 vs ALID: -3.10

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Allied's stock price is $0.1473. Allied's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.090. Therefore, Allied's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Allied EV-to-EBITDA Historical Data

The historical data trend for Allied's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allied EV-to-EBITDA Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23
EV-to-EBITDA
Get a 7-Day Free Trial - -22.33 -9.19 -3.39 -3.05

Allied Quarterly Data
Mar19 Jun19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.42 -6.11 -3.05 -1.62 -1.18

Competitive Comparison of Allied's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allied's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Allied's EV-to-EBITDA falls into.



Allied EV-to-EBITDA Calculation

Allied's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=24.769/-7.987
=-3.10

Allied's current Enterprise Value is $24.77 Mil.
Allied's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allied  (OTCPK:ALID) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Allied's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1473/-0.090
=At Loss

Allied's share price for today is $0.1473.
Allied's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.090.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Allied EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Allied's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Allied (Allied) Business Description

Traded in Other Exchanges
N/A
Address
1405 St. Paul Street, Suite 201, Kelowna, BC, CAN, V1Y 9N2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised ofsales ofcannabis products.
Executives
James George Robinson director, 10 percent owner 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Anthony Zelen director, 10 percent owner 1406 MINE HILL LANE, KELOWNA A1 V1P 1S5
Calum Hughes director, 10 percent owner, officer: Chief Executive Officer 1847 CROSSGLEN COURT, KELOWNA A1 V1V 1S4
David Weinkauf director, 10 percent owner, officer: Chief Business Development Off 192 SIERRA MORENA LANDING, SW CALGARY A0 T3H 4K4
Paul James Bullock director, 10 percent owner, officer: Chief Operating Officer 1400 ST PAUL ST, SUITE 201, KELOWNA Z4 V1Y9N2